Neovascular Age Related Macular Degeneration Clinical Trial
Official title:
A Phase 1, Dose-Escalating, Multi-Center, Study of iSONEP (Sonepcizumab [LT1009]) Administered as an Intravitreal Injection to Subjects With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a disease that, in time, destroys the macula, which is the central part of the retina that gives sharp central vision. The primary purpose of this study is to assess the safety of iSONEP which is a humanized monoclonal antibody against a bioactive lipid, sphingosine 1-phosphate (S1P).
S1P modulates the AMD-associated processes of angiogenesis, inflammation and fibrosis. A potential strategy for treating choroidal neovascularization associated with AMD is to reduce the biologically available extracellular levels of S1P. iSONEP is highly selective for S1P and binds with picomolar affinity. Lpath proposes that iSONEP would deprive many cell types (fibroblasts, pericytes, vascular endothelial cells and inflammatory) of important growth and survival factors thus targeting the multiple maladaptive processes of exudative AMD that ultimately result in the loss of photoreceptors, their supporting cells, and visual acuity. Targeting simultaneously multiple components of the choroidal neovascular response is a novel approach and has the potential to be more potent than "single-targeted" therapeutics such as anti-VEGF therapies. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02251366 -
NVAMD Satellite Study
|
N/A | |
| Completed |
NCT00764738 -
Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
|
Phase 2/Phase 3 | |
| Completed |
NCT00383370 -
Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
|
Phase 1 | |
| Completed |
NCT01678963 -
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
|
Phase 2 | |
| Completed |
NCT03930641 -
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
|
Phase 3 | |
| Completed |
NCT01863199 -
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
|
Phase 4 | |
| Recruiting |
NCT05562947 -
A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration
|
Phase 3 | |
| Completed |
NCT04239027 -
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
|
Phase 3 | |
| Completed |
NCT00574093 -
Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
|
Phase 2 | |
| Completed |
NCT00685100 -
Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone
|
Phase 3 | |
| Completed |
NCT01942213 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.
|
N/A | |
| Recruiting |
NCT00640640 -
The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)
|
N/A |